Bruce Gillis, M.D., M.P.H., medical toxicologist and CEO of The Cytokine Institute research group, recently presented a tutorial on new genomics-based technology called msds1and how it will impact workers’ compensation claims at the International Congress of Toxicology in Montreal.

The technology analyzes gene expression and how 36,000 parameters of an individual’s DNA are affected by exposure to chemicals, such as benzene or asbestos. Msds1 can determine with 99.9 percent certainty if a person was exposed to dangerous levels of a particular toxin, providing an impartial methodology for producing scientifically-based evidence to help reduce fraudulent claims.

Want to continue reading?
Become a Free
PropertyCasualty360 Digital Reader.


  • All news coverage, best practices, and in-depth analysis.
  • Educational webcasts, resources from industry leaders, and informative newsletters.
  • Other award-winning websites including and

Already have an account?



Join PropertyCasualty360

Don’t miss crucial news and insights you need to make informed decisions for your P&C insurance business. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including, and
  • Exclusive discounts on PropertyCasualty360, National Underwriter, Claims and ALM events

Already have an account? Sign In Now
Join PropertyCasualty360

Copyright © 2022 ALM Global, LLC. All Rights Reserved.